JP2017526706A - イソオキサゾールカルボキサミド化合物 - Google Patents

イソオキサゾールカルボキサミド化合物 Download PDF

Info

Publication number
JP2017526706A
JP2017526706A JP2017513199A JP2017513199A JP2017526706A JP 2017526706 A JP2017526706 A JP 2017526706A JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017526706 A JP2017526706 A JP 2017526706A
Authority
JP
Japan
Prior art keywords
cancer
alkyl
tumor
cell
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526706A5 (enExample
Inventor
アリーン クルーナン フォーリー メーガン
アリーン クルーナン フォーリー メーガン
ウェイン クンツ ケヴィン
ウェイン クンツ ケヴィン
エドワード ジョン ミルズ ジェイムス
エドワード ジョン ミルズ ジェイムス
ヘレン ミッチェル ローナ
ヘレン ミッチェル ローナ
ジョン マンチホフ マイケル
ジョン マンチホフ マイケル
マーティン ハーヴィー ダレン
マーティン ハーヴィー ダレン
Original Assignee
エピザイム，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム，インコーポレイティド filed Critical エピザイム，インコーポレイティド
Publication of JP2017526706A publication Critical patent/JP2017526706A/ja
Publication of JP2017526706A5 publication Critical patent/JP2017526706A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017513199A 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物 Pending JP2017526706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048759P 2014-09-10 2014-09-10
US62/048,759 2014-09-10
US201562146794P 2015-04-13 2015-04-13
US62/146,794 2015-04-13
PCT/US2015/049213 WO2016040498A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017526706A true JP2017526706A (ja) 2017-09-14
JP2017526706A5 JP2017526706A5 (enExample) 2018-10-18

Family

ID=55459522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513199A Pending JP2017526706A (ja) 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物

Country Status (6)

Country Link
US (2) US10428029B2 (enExample)
EP (1) EP3193603A4 (enExample)
JP (1) JP2017526706A (enExample)
AU (1) AU2015315167A1 (enExample)
CA (1) CA2960274A1 (enExample)
WO (1) WO2016040498A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528464A (ja) * 2014-09-10 2017-09-28 エピザイム，インコーポレイティド 置換ピペリジン化合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
JP2017528460A (ja) 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
WO2016204006A1 (ja) 2015-06-17 2016-12-22 住友化学株式会社 有害節足動物防除剤
CU20210018A7 (es) * 2018-09-21 2021-10-12 Novartis Ag Compuestos de isoxazol-3-carboxamida
CN109879868B (zh) * 2019-03-07 2022-04-22 南通大学 含2-芳基噁唑结构的吡唑酰胺类化合物的制备和应用

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065225A (en) * 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
WO2001002350A2 (de) * 1999-06-30 2001-01-11 Bayer Aktiengesellschaft Neue amino- und amidosulfonamide als antivirale mittel
US20040147517A1 (en) * 2000-07-17 2004-07-29 Jelley Richard Alexander Imidazolophthalazine derivatives as ligands for gabaa receptors
JP2004537526A (ja) * 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド 片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
WO2005004810A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
JP2006517563A (ja) * 2003-02-14 2006-07-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−アリール複素環化合物、その製造方法およびその医薬としての使用
US20060223873A1 (en) * 2005-03-29 2006-10-05 Jiajiu Shaw Isoxazole derivatives and methods of treating nitric oxide mediated diseases
WO2008040149A1 (en) * 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
JP2008525406A (ja) * 2004-12-22 2008-07-17 アストラゼネカ アクチボラグ 抗がん剤として使用するためのピリジンカルボキサミド誘導体
WO2008124849A2 (en) * 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP2009514937A (ja) * 2005-11-04 2009-04-09 ファイザー・リミテッド ピラジン誘導体
JP2010526050A (ja) * 2007-05-03 2010-07-29 ファイザー・リミテッド ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
JP2013518099A (ja) * 2010-01-29 2013-05-20 ハンミ・サイエンス・カンパニー・リミテッド プロテインキナーゼ阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
WO2014150326A1 (en) * 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
JP2016501110A (ja) * 2012-12-18 2016-01-18 アルキオーネ・ライフサイエンシズ・インコーポレイテッドＡｌｃｙｏｎｅ Ｌｉｆｅｓｃｉｅｎｃｅｓ， Ｉｎｃ． 送達システムにおける逆流を低減または防止するシステムおよび方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
US20170247326A1 (en) 2014-09-10 2017-08-31 Epizyme, Inc. Substituted Pyrrolidine Carboxamide Compounds
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Ｓｍｙｄ 억제제
JP2017528460A (ja) 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
US20170253601A1 (en) * 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065225A (en) * 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
WO2001002350A2 (de) * 1999-06-30 2001-01-11 Bayer Aktiengesellschaft Neue amino- und amidosulfonamide als antivirale mittel
US20040147517A1 (en) * 2000-07-17 2004-07-29 Jelley Richard Alexander Imidazolophthalazine derivatives as ligands for gabaa receptors
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
JP2004537526A (ja) * 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド 片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
JP2006517563A (ja) * 2003-02-14 2006-07-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−アリール複素環化合物、その製造方法およびその医薬としての使用
WO2005004810A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
JP2008525406A (ja) * 2004-12-22 2008-07-17 アストラゼネカ アクチボラグ 抗がん剤として使用するためのピリジンカルボキサミド誘導体
US20060223873A1 (en) * 2005-03-29 2006-10-05 Jiajiu Shaw Isoxazole derivatives and methods of treating nitric oxide mediated diseases
JP2009514937A (ja) * 2005-11-04 2009-04-09 ファイザー・リミテッド ピラジン誘導体
WO2008040149A1 (en) * 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
WO2008124849A2 (en) * 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP2010526050A (ja) * 2007-05-03 2010-07-29 ファイザー・リミテッド ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体
JP2013518099A (ja) * 2010-01-29 2013-05-20 ハンミ・サイエンス・カンパニー・リミテッド プロテインキナーゼ阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
JP2016501110A (ja) * 2012-12-18 2016-01-18 アルキオーネ・ライフサイエンシズ・インコーポレイテッドＡｌｃｙｏｎｅ Ｌｉｆｅｓｃｉｅｎｃｅｓ， Ｉｎｃ． 送達システムにおける逆流を低減または防止するシステムおよび方法
WO2014150326A1 (en) * 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. ２２, JPN6019016833, 2012, pages 3269 - 3273, ISSN: 0004030931 *
EUR. J. MED. CHEM., vol. ２７, JPN6019016828, 1992, pages 581 - 593, ISSN: 0004030927 *
J. CHEMINFORMATICS, vol. ４, JPN6019016832, 2012, pages １６, ISSN: 0004030930 *
J. MED. CHEM., vol. ５５, JPN6019016830, 2012, pages 9793 - 9809, ISSN: 0004030928 *
PUBCHEM, JPN6019016823, 2012, pages 61803752, ISSN: 0004030924 *
PUBCHEM, JPN6019016825, 2007, pages 16677096, ISSN: 0004030925 *
PUBCHEM, JPN6019016826, 2012, pages 61574221, ISSN: 0004030926 *
REGISTRY（STN）［ONLINE］, JPN7019001442, 2014, pages 912879 - 90, ISSN: 0004030929 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528464A (ja) * 2014-09-10 2017-09-28 エピザイム，インコーポレイティド 置換ピペリジン化合物

Also Published As

Publication number Publication date
AU2015315167A1 (en) 2017-03-16
US20200148650A1 (en) 2020-05-14
CA2960274A1 (en) 2016-03-17
US20170190676A1 (en) 2017-07-06
EP3193603A4 (en) 2018-02-28
EP3193603A1 (en) 2017-07-26
US10428029B2 (en) 2019-10-01
WO2016040498A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
JP2020090520A (ja) Ｓｍｙｄ阻害剤
JP7256823B2 (ja) メチル修飾酵素のモジュレーター、その組成物および使用
JP2017526706A (ja) イソオキサゾールカルボキサミド化合物
KR102475498B1 (ko) 리신 특이적 데메틸라아제-1의 억제제
JP2017527577A (ja) 置換ピロリジン化合物
US10577363B2 (en) Substituted piperidine compounds
US20200048195A1 (en) Substituted pyrrolidine carboxamide compounds
JP2017528460A (ja) 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド
JP2017527576A (ja) 置換シクロヘキシルアミン化合物
US20200123142A1 (en) Substituted Cyclohexylamine Compounds
JP2024528729A (ja) Ｓｒｐｋインヒビター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191203